iCAD to Report Second Quarter 2024 Financial Results on August 13, 2024
iCAD Inc (NASDAQ: ICAD), a leader in AI-powered cancer detection solutions, has announced its plan to release Q2 2024 financial results on August 13, 2024, after market close. The company will host a conference call at 4:30 PM Eastern Time on the same day to discuss the results. Investors and analysts can access the call via toll-free number 888-506-0062 (US) or 973-528-0011 (International) using the participant access code 227167. A webcast of the earnings call will also be available for those who prefer to listen online.
iCAD Inc (NASDAQ: ICAD), un leader nelle soluzioni di rilevamento del cancro alimentate dall'IA, ha annunciato il suo piano per rilasciare i risultati finanziari del II trimestre 2024 il 13 agosto 2024, dopo la chiusura del mercato. L'azienda organizzerà una conferenza telefonica alle 16:30 ora orientale lo stesso giorno per discutere i risultati. Investitori e analisti possono accedere alla chiamata tramite il numero verde 888-506-0062 (USA) o 973-528-0011 (Internazionale) utilizzando il codice di accesso per i partecipanti 227167. Sarà inoltre disponibile una trasmissione web della chiamata sugli utili per coloro che preferiscono ascoltare online.
iCAD Inc (NASDAQ: ICAD), líder en soluciones de detección de cáncer impulsadas por IA, ha anunciado su plan para publicar los resultados financieros del segundo trimestre de 2024 el 13 de agosto de 2024, después del cierre del mercado. La empresa llevará a cabo una llamada de conferencia a las 4:30 PM, hora del Este el mismo día para discutir los resultados. Inversores y analistas pueden acceder a la llamada a través del número gratuito 888-506-0062 (EE. UU.) o 973-528-0011 (Internacional) utilizando el código de acceso para los participantes 227167. También estará disponible una transmisión en línea de la llamada sobre los resultados para aquellos que prefieren escuchar por Internet.
iCAD Inc (NASDAQ: ICAD), AI 기반의 암 감지 솔루션의 선두주자인 이 회사는 2024년 2분기 재무 결과를 2024년 8월 13일, 시장 마감 후 발표할 계획이라고 발표했습니다. 회사는 같은 날 동부 표준시 4:30 PM에 결과를 논의하기 위해 컨퍼런스 콜을 열 것입니다. 투자자 및 애널리스트는 참가자 접근 코드 227167을 사용하여 무료 전화번호 888-506-0062(미국) 또는 973-528-0011(국제전화)로 호출에 참여할 수 있습니다. 온라인으로 듣기를 선호하는 사람들을 위해 수익 콜의 웹 캐스트도 제공될 예정입니다.
iCAD Inc (NASDAQ: ICAD), un leader dans les solutions de détection du cancer alimentées par l'IA, a annoncé son intention de publier les résultats financiers du deuxième trimestre 2024 le 13 août 2024, après la fermeture du marché. La société tiendra une conférence téléphonique à 16h30 heure de l'Est le même jour pour discuter des résultats. Les investisseurs et les analystes peuvent accéder à l'appel via le numéro gratuit 888-506-0062 (États-Unis) ou 973-528-0011 (International) en utilisant le code d'accès des participants 227167. Un webinaire des résultats sera également disponible pour ceux qui préfèrent écouter en ligne.
iCAD Inc (NASDAQ: ICAD), ein führendes Unternehmen im Bereich KI-gesteuerter Krebsdiagnoselösungen, hat seinen Plan bekannt gegeben, die finanziellen Ergebnisse des 2. Quartals 2024 am 13. August 2024 nach Börsenschluss zu veröffentlichen. Das Unternehmen wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren und Analysten können über die gebührenfreie Nummer 888-506-0062 (USA) oder 973-528-0011 (International) auf den Anruf zugreifen, indem sie den Teilnehmerzugangscode 227167 verwenden. Ein Webcast des Gewinnaufrufs wird ebenfalls für diejenigen verfügbar sein, die online zuhören möchten.
- Timely financial reporting indicates transparency and adherence to regulatory requirements
- Hosting an earnings call suggests openness to investor communication
- None.
NASHUA, N.H., Aug. 06, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the second quarter ended June 30, 2024 after market close and host a conference call at 4:30 PM Eastern Time on Tuesday, August 13, 2024.
Earnings call details are as follows:
Toll Free: 888-506-0062
International: 973-528-0011
Participant Access Code: 227167
Webcast: https://www.webcaster4.com/Webcast/Page/2879/50989
About iCAD, Inc.
iCAD, Inc. (NASDAQ: ICAD) is a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered solutions that enable medical providers to accurately and reliably detect cancer earlier and improve patient outcomes. Headquartered in Nashua, N.H., iCAD’s industry-leading ProFound Breast Health Suite provides AI-powered mammography analysis for breast cancer detection, density assessment, and risk evaluation. Used by thousands of providers serving millions of patients, ProFound is available in over 50 countries. In the last five years alone, iCAD estimates reading more than 40 million mammograms worldwide, with nearly
Forward-Looking Statements
Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about the expansion of access to the Company’s products, improvement of performance, acceleration of adoption, expected benefits of ProFound AI®, the benefits of the Company’s products, and future prospects for the Company’s technology platforms and products. Such forward-looking statements involve a number of known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited, to the Company’s ability to achieve business and strategic objectives, the willingness of patients to undergo mammography screening in light of risks of potential exposure to Covid-19, whether mammography screening will be treated as an essential procedure, whether ProFound AI will improve reading efficiency, improve specificity and sensitivity, reduce false positives and otherwise prove to be more beneficial for patients and clinicians, the impact of supply and manufacturing constraints or difficulties on our ability to fulfill our orders, uncertainty of future sales levels, to defend itself in litigation matters, protection of patents and other proprietary rights, product market acceptance, possible technological obsolescence of products, increased competition, government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe,” “demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC’s website at http://www.sec.gov.
CONTACTS
Media inquiries: pr@icadmed.com
Investor Inquiries:
John Nesbett/Rosalyn Christian
IMS Investor Relations
icad@imsinvestorrelations.com
FAQ
When will iCAD (ICAD) release its Q2 2024 financial results?
What time is iCAD's (ICAD) Q2 2024 earnings call scheduled for?
How can investors access iCAD's (ICAD) Q2 2024 earnings call?
What is the participant access code for iCAD's (ICAD) Q2 2024 earnings call?
